COBRE/Tropical Medicine Seminar

May 20, 12:00pm - 1:00pm
Mānoa Campus, John A. Burns School of Medicine, Kaka芒鈧劉ako Campus, 651 Ilalo Street, MEB Auditorium (Room 315)

"Antiviral Activity of Favipiravir Against Henipaviruses" by Alexander Freiberg, Ph.D., Assistant Professor, Department of Pathology, Director, Robert E. Shope BSL-4 Laboratory, University of Texas Medical Branch, Galveston, Texas Nipah virus (NiV) and Hendra virus are recently emerged bat-borne paramyxoviruses of the Henipavirus genus which cause severe acute respiratory and encephalitic diseases in humans. The case-fatality rate ranges from 40-90%, depending on the size of the outbreak. Currently, no vaccines or therapeutics are approved for use in humans. Favipiravir (T-705) is an RNA-dependent RNA polymerase inhibitor that has been approved for use against influenza virus in Japan and has displayed broad-spectrum efficacy against multiple RNA viruses (including filo-, arena- and bunyaviruses). Here, we demonstrate the in vitro activity of T-705 against henipaviruses and in vivo efficacy in a small animal model for NiV.


Event Sponsor
Pacific Center for Emerging Infectious Diseases Research/JABSOM Tropical Med., Mānoa Campus

More Information
Cori Watanabe, (808) 692-1654, corit@hawaii.edu, Freiberg seminar (PDF)

Share by email